The ARIA/EAACI criteria for antihistamines: an assessment of the efficacy, safety and pharmacology of desloratadine
- 5 July 2004
- Vol. 59 (s77) , 4-16
- https://doi.org/10.1111/j.1398-9995.2004.00577.x
Abstract
The definition of allergic rhinitis and the classification of its severity and treatment have advanced in recent years following the publication of the Allergic Rhinitis and its Impact of Asthma (ARIA) document. The ARIA and the European Academy of Allergology and Clinical Immunology (ARIA/EAACI) have published a set of recommendations that outline the pharmacological and clinical criteria to be met by medications commonly used in the treatment of allergic rhinitis. An international group of experts met to assess the profile of the antihistamine, desloratadine, under the ARIA/EAACI criteria. Data on desloratadine were collected from peer-reviewed clinical studies and review articles, which were corroborated and augmented by comprehensive public access documents from the European Medicines Evaluation Agency (EMEA). Based on this systematic review, it was concluded that the efficacy, safety and pharmacology of desloratadine broadly meet the ARIA/EAACI criteria for antihistamines.Keywords
This publication has 39 references indexed in Scilit:
- A comparison of the effect of diphenhydramine and desloratadine on vigilance and cognitive function during treatment of ragweed-induced allergic rhinitisAnnals of Allergy, Asthma & Immunology, 2003
- Comparative Effects of Desloratadine versus Montelukast on Asthma Symptoms and Use of β2-Agonists in Patients with Seasonal Allergic Rhinitis and AsthmaInternational Archives of Allergy and Immunology, 2003
- Safety and efficacy of desloratadine 5 mg in asthma patients with seasonal allergic rhinitis and nasal congestionAnnals of Allergy, Asthma & Immunology, 2002
- Desloratadine in the Treatment of Seasonal Allergic RhinitisClinical Drug Investigation, 2002
- Decongestant Activity of Desloratadine in Controlled-Allergen-Exposure TrialsClinical Drug Investigation, 2002
- Grapefruit Juice Reduces the Oral Bioavailability of Fexofenadine But Not DesloratadineClinical Pharmacokinetics, 2002
- Effect of desloratadine and loratadine on rhinovirus-induced intercellular adhesion molecule 1 upregulation and promoter activation in respiratory epithelial cellsJournal of Allergy and Clinical Immunology, 2001
- Efficacy and Tolerability of Once-Daily 5mg Desloratadine, an H1-Receptor Antagonist, in Patients with Seasonal Allergic RhinitisClinical Drug Investigation, 2001
- Inhibitory activity of loratadine and descarboxyethoxyloratadine on histamine-induced activation of endothelial cellsClinical and Experimental Allergy, 1997
- Inhibitory activity of loratadine and descarboxyethoxyloratadine on histamine-induced activation of endothelial cellsClinical and Experimental Allergy, 1997